CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Gefapixant 50 mg +3 moredrug
Likely dose
Gefapixant 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01993329
NCT01993329Phase 2Completed
CompareCT.gov

A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-Reactivity in Subjects With Asthma

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Nov 25, 2013·Updated Feb 3, 2021

In Brief

A Phase 2 clinical trial evaluating Gefapixant 50 mg, Gefapixant 300 mg, and 2 other interventions for Asthma. Completed, enrolled 20 participants.

Detailed Summary

This is a randomized, double-blind, double-dummy, placebo-controlled, three-way cross-over, single centre study in participants with asthma undergoing inhalation of methacholine and adenosine triphosphate (ATP) to assess the provocative concentration (PC20) response of two dose levels of gefapixant (AF-219) compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartDec 16, 2013
Primary CompletionFeb 20, 2014
Study CompletionFeb 28, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.6 years ago

Interventions

Gefapixant 50 mgdrug

Gefapixant 50 mg tablet administered orally

Gefapixant 300 mgdrug

Gefapixant 300 mg tablet administered orally

Placebo to mimic 50 mg tabletsdrug

Sugar pill manufactured to mimic gefapixant 50 mg tablets

Placebo to mimic 300 mg tabletsdrug

Sugar pill manufactured to mimic gefapixant 300 mg tablets